Precision Wealth Strategies LLC Buys Shares of 10,458 Halozyme Therapeutics, Inc. $HALO

Precision Wealth Strategies LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 10,458 shares of the biopharmaceutical company’s stock, valued at approximately $767,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HALO. Redhawk Wealth Advisors Inc. raised its holdings in Halozyme Therapeutics by 14.8% during the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock valued at $1,947,000 after acquiring an additional 4,827 shares during the period. Monument Capital Management purchased a new position in shares of Halozyme Therapeutics in the third quarter valued at $2,015,000. Intech Investment Management LLC raised its stake in shares of Halozyme Therapeutics by 9.9% during the 1st quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock valued at $9,776,000 after purchasing an additional 13,789 shares during the period. BI Asset Management Fondsmaeglerselskab A S raised its stake in shares of Halozyme Therapeutics by 19.1% during the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 444,947 shares of the biopharmaceutical company’s stock valued at $23,146,000 after purchasing an additional 71,455 shares during the period. Finally, HRT Financial LP lifted its holdings in Halozyme Therapeutics by 576.1% during the 2nd quarter. HRT Financial LP now owns 467,070 shares of the biopharmaceutical company’s stock worth $24,296,000 after purchasing an additional 397,985 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $68.44 on Friday. The business’s 50-day moving average price is $67.30 and its 200-day moving average price is $65.31. The firm has a market capitalization of $8.05 billion, a PE ratio of 14.41, a price-to-earnings-growth ratio of 0.37 and a beta of 0.95. Halozyme Therapeutics, Inc. has a 12 month low of $46.99 and a 12 month high of $79.50. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period last year, the business earned $1.27 earnings per share. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction dated Saturday, November 1st. The stock was sold at an average price of $65.19, for a total value of $277,904.97. Following the transaction, the chief operating officer owned 12,737 shares in the company, valued at approximately $830,325.03. The trade was a 25.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Helen Torley sold 16,569 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the sale, the chief executive officer owned 708,719 shares of the company’s stock, valued at $48,844,913.48. This represents a 2.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 85,661 shares of company stock valued at $6,036,837 over the last three months. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on HALO shares. Morgan Stanley reduced their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. The Goldman Sachs Group restated a “sell” rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Weiss Ratings restated a “hold (c+)” rating on shares of Halozyme Therapeutics in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Friday, December 19th. Finally, Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 6th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Hold” and an average target price of $75.10.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.